Bone marrow findings in blast phase of polycythemia vera

Annals of Hematology
Juliana E Hidalgo LópezGuilin Tang

Abstract

Approximately 10% of patients with polycythemia vera (PV) transform to acute leukemia (blast phase) at 10 years after initial diagnosis of PV. The bone marrow pathologic, cytogenetic, and molecular features of blast phase have not been well characterized. In this study, we reviewed 422 PV patients over a period of 11 years and identified 58 patients who developed acute myeloid leukemia (blast phase) during the course of disease. We found that blast phase of PV was characterized by overt myelodysplasia (n = 51, 88%); moderate to severe myelofibrosis (33 of 45, 73%); an abnormal karyotype (n = 51, 88%) that was often complex karyotype (n = 42, 72%); and gene mutations involving TP53 (55%), TET2 (27%), and DNMT3A (25%). Patients with blast phase of PV had an aggressive clinical course, with a median overall survival of 4 months after onset of blast phase. Eleven patients had close follow-up from polycythemic phase to blast phase: Four patients showed dysplastic changes in the polycythemic phase, and three of them transformed to blast phase without a "middle phase" of post-PV myelofibrosis.We conclude that blast phase of PV is characterized by myelodysplasia, moderate to severe fibrosis, a high frequency of an abnormal and often co...Continue Reading

References

Oct 1, 1979·British Journal of Haematology·A ManoharanW R Pitney
Feb 26, 1999·Leukemia & Lymphoma·M CamósE Montserrat
Feb 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roberto MarchioliTiziano Barbui
Jul 28, 2005·Cancer·Francesco PassamontiMario Lazzarino
Jul 7, 2007·British Journal of Haematology·Naseema GangatAyalew Tefferi
Feb 4, 2011·The New England Journal of Medicine·Ashot HarutyunyanRobert Kralovics
May 4, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Magnus BjörkholmOla Landgren
Jun 3, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christoph RölligGerhard Ehninger
Mar 16, 2013·Leukemia & Lymphoma·Matjaz SeverSrdan Verstovsek
May 3, 2013·The New England Journal of Medicine·UNKNOWN Cancer Genome Atlas Research NetworkGreg Eley
Jul 3, 2013·Cytogenetic and Genome Research·A SimonsR J Hastings
Dec 25, 2013·Current Opinion in Hematology·Raajit Rampal, John Mascarenhas
Jun 28, 2014·American Journal of Hematology·Glen J TitmarshLesley A Anderson
Sep 6, 2014·Best Practice & Research. Clinical Haematology·Magnus BjörkholmÅsa Rangert Derolf
Jul 18, 2015·American Journal of Clinical Pathology·Magdalena Czader, Attilio Orazi
Sep 2, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brady L SteinRonald Hoffman
Jul 14, 2016·Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion·Władysław B GawełSławomira Kyrcz-Krzemień
Dec 20, 2016·American Journal of Hematology·Ayalew Tefferi, Tiziano Barbui

❮ Previous
Next ❯

Citations

Jun 4, 2019·Blood·Jerry L Spivak
Nov 8, 2018·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Guilin TangSa A Wang
Feb 27, 2021·Vox Sanguinis·Jeffrey S Putter, Jerard Seghatchian

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease & TET2

Cardiovascular diseases are the number one cause of deaths globally. Tet methylcytosine dioxygenase 2 (TET2)-mediated hematopoiesis has been implicated in accelerating heart failure. Here is the latest research on cardiovascular diseases and TET2.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.